BioSpace News Archive

Drug Development

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

Rocket Pharmaceuticals, Inc. announces positive clinical updates from its Phase 1 Danon Disease Trial for RP-A501 through an oral poster session at the Heart Failure Society of America Annual Scientific Meeting 2022.

September 30, 2022
·
14 min read
Drug Development

Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)

Zealand Pharma A/S announced positive topline results from the pivotal Phase 3 trial of glepaglutide, a long-acting GLP-2 analogue designed for once or twice weekly subcutaneous delivery via auto-injector, in patients with short bowel syndrome.

September 30, 2022
·
9 min read
Genetown

KalVista Pharmaceuticals to Present at the 2022 HAEi Global Leadership Workshop

KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2022 HAE International Global Leadership Workshop taking place in Frankfurt, Germany from October 6-9.

September 30, 2022
·
4 min read
Deals

Zoetis Announces the Completion of its Acquisition of Jurox, a Leading Provider of Livestock and Companion Animal Products

Zoetis Inc today announced it has completed the acquisition of Jurox, a privately held animal health company that develops, manufactures and markets a wide range of veterinary medicines for treating livestock and companion animals.

September 30, 2022
·
4 min read
IMV Provides an Update on The VITALIZE Trial

IMV Inc. today provided an update on the open-label VITALIZE study evaluating its lead product maveropepimut-S (MVP-S) in combination with pembrolizumab and intermittent low-dose cyclophosphamide (CPA) in patients with relapses, refractory diffuse large B cell lymphoma (r/r DLBCL).

September 30, 2022
·
5 min read
Deals

BiondVax announces financial plans to support its ongoing NanoAb pipeline development

BiondVax Pharmaceuticals Ltd. announced the filing yesterday of a Registration Statement (“Form F-1") with the US Securities and Exchange Commission (“SEC”) for a firm commitment underwritten offering of BiondVax American Depositary Shares (“ADSs”).

September 30, 2022
·
7 min read
Drug Development

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint

Intercept Pharmaceuticals, Inc. today announced that REVERSE, a Phase 3 study evaluating the safety and efficacy of OCA in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH).

September 30, 2022
·
5 min read
Genetown

Mersana Therapeutics Announces Launch of Oncology FACETS, a Resource for Healthcare Providers to Advance Knowledge in Gynecologic Malignancies

Mersana Therapeutics, Inc. today announced the launch of Oncology FACETS : an educational platform for healthcare providers that will address clinically impactful topics in gynecologic oncology.

September 30, 2022
·
4 min read
BioCapital

Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma

Synthetic Biologics, Inc. today announced the presentation of new data from collaborators at Fundació Sant Joan de Déu that further support evaluation of VCN-01, an oncolytic adenovirus expressing hyaluronidase, and topotecan for the treatment of refractory retinoblastoma.

September 30, 2022
·
6 min read
Genetown

Results of the Insulin-Only Bionic Pancreas Pivotal Trial, Which Were Presented at ADA’s 82nd Scientific Sessions, Are Published This Week in the New England Journal of Medicine

Beta Bionics, Inc. — The results of the multi-center randomized Insulin-Only Bionic Pancreas Pivotal Trial, which were presented in June at the 82nd Scientific Sessions of the American Diabetes Association, are published this week in the New England Journal of Medicine.

September 30, 2022
·
7 min read